Kornimate/medical-research-clean huggingface dataset:
study of therapeutic value of periorbital injection of glucocorticoid in mild tao

Conditions: Thyroid Associated Ophthalmopathy

Summary: the purpose of this study is to determine whether periorbital injection of glucocorticoid is effective and necessary in the treatment of mild tao.


Eligibility criteria:
inclusion criteria: general conditions: 1. clinically diagnosed as thyroid disease; 2. able and willing to participate in clinical trials and ensure regular follow-up. eye condition: 1. patients with monocular disease diagnosed by tao; 2. eugogo/nospecs grade was mild and cas score was less than 3; 3. the course of eye disease was less than 12mo and had not been treated in the past. exclusion criteria: general situation: 1. patients with poor blood glucose control in recent 3 months, glycosylation ≥ 10% ; 2. blood pressure still fluctuated \> 180/110mmhg after medication; 3. obvious liver and kidney insufficiency; 4. contraindications for the use of glucocorticoids (peptic ulcer, osteoporosis, severe infection, psychosis, etc.); 5. patients with severe abnormal blood coagulation; 6. patients with other systemic immune diseases; 7. any uncontrollable clinical problems (severe mental, neurological, cardiovascular, respiratory and other systemic diseases and malignant tumors); 8. history of chronic infection; 9. pregnant and lactating women. eye conditions: 1. b-ultrasound or ct, mri found other diseases causing exophthalmos (intraorbital space occupying lesion, inflammatory pseudotumor, neurofibroma, etc.); 2. moderate to severe tao, in either eye requiring local or systemic treatment; 3. periorbital infectious diseases, hemorrhagic diseases; 4. uveitis, glaucoma, high myopia, diabetic retinopathy and other eye diseases. 5. those who studied the eyes who had a history of arbitrary surgery; 6. those who were considered by the researchers to be excluded.
impulse oscillometry for prognostication in idiopathic pulmonary fibrosis

Conditions: Idiopathic Pulmonary Fibrosis

Summary: a 5-point decline of forced vital capacity expressed as % predicted, over 6 months, is the current definition of disease progression (fast decline in lung function) in idiopathic pulmonary fibrosis. there is a need for techniques allowing to characterize disease progression earlier, so that treatment may be adapted as early as possible in the lack of a response. hypothesis. our hypothesis is that 3-month changes of lung function parameters measured by a novel technique, impulse oscillometry, predicts 6-month changes in forced vital capacity in idiopathic pulmonary fibrosis.

a 5-point decline of forced vital capacity expressed as % predicted, over 6 months, is the current definition of disease progression (fast decline in lung function) in idiopathic pulmonary fibrosis. there is a need for techniques allowing to characterize disease progression earlier, so that treatment may be adapted as early as possible in the lack of a response. hypothesis. our hypothesis is that 3-month changes of lung function parameters measured by a novel technique, impulse oscillometry, predicts 6-month changes in forced vital capacity in idiopathic pulmonary fibrosis.

Eligibility criteria:
inclusion criteria: * age ≥ 45 years. * idiopathic pulmonary fibrosis defined interstitial lung diseases with 1) lack of any known cause for interstitial lung diseases and 2) either the "definite usual interstitial pneumonia" pattern at ct scan, or the usual interstitial pneumonia (definite, probable or possible) pattern at lung biopsy, according to the lung function group of the french pulmonology society criteria. exclusion criteria: * history of chronic obstructive airway disease. * history of congestive heart failure. * emphysema-fibrosis syndrome, defined as emphysematous lesions involving \>15% of the lung area at the level of the aortic arch (upper lobes). * history of lower respiratory infection or acute respiratory failure of any cause less than 90 days before inclusion. * opposition to data processing.

Keywords: idiopathic pulmonary fibrosis impulse oscillometry forced vital capacity
following the use of gel prosethetics in breast reconstruction

Conditions: Breast Cancer

Summary: following placement of silicone breast prosthetics for reconstruction

patients undergoing breast reconstruction will be followed for outcomes after placement of silicone prostheses

Eligibility criteria:
inclusion criteria: * women undergoing breast surgery exclusion criteria: * collagen vascular disease, scleroderma

Keywords: reconstruction, silicone prostheses
accuracy of iccms versus simplified cariogram

Conditions: Caries,Dental

Summary: the study aims to compare the validity of the caries risk assessment regarding the comprehensive iccms caries risk and likelihood matrix versus the simplified cariogram aiming to see if there is a significant difference in the caries risk levels between both models.

the simplified cariogram has been already established as a simple computerised efficient way to categorise patients according to their risk of developing new lesions. however, since then, more comprehensive ways such as the iccms have risen. such comprehensive models require much more data to be entered and more time for the assessment to be complete. this study aims to test whether there is a significant difference between the validity of both models that would justify the extra time, effort, and recordings that have to be taken for the iccms.

Eligibility criteria:
inclusion criteria: * age ranging from 18 to 29 years. * the presence of dental caries or restoration. exclusion criteria: * patients with no caries. * patients diagnosed of psychiatric disease. * patients not willing to be part of the study or ones who refuse to sign the informed consent.

Keywords: risk validity cariogram iccms
clinical study of regeneration on larynx soft tissue guided by functional collagen scaffold

Conditions: Vocal Cord Dysfunction

Summary: this study is carried out to explore the short-term and long-term efficacy of the functional collagen scaffold in guiding laryngeal soft tissue regeneration.


Eligibility criteria:
inclusion criteria: 1. age of 18-65 years old, male or female 2. severe unilateral vocal cord injury and poor closure of the glottis 3. disease course was more than 1 year 4. at least two grbas scores reach 2 points or more 5. the subjects have read and fully understood the research notes, signed informed consent exclusion criteria: 1. over speaking professionals, such as teachers, shop assistants. 2. with vital organ dysfunction, such as heart, lung, liver or kidney. 3. pregnant or lactating women, or in preconception period. 4. allergic to various drugs. 5. difficult to be followed-up or cooperate long-termly. 6. participated in other clinical trials in the last 3 months. 7. with progressive severe disease. 8. alcoholics or drug addicts. 9. unable to execute clinical study protocol due to severe mental disorders or lingual barriers 10. with inevitable circumstances of voice damage. 11. any other unsuitable conditions for the study.
building a platform for precision anesthesia in the geriatric surgical patient

Conditions: Cognitive Decline; Cognitive Change; Cognitive Impairment; Postoperative Delirium; Anesthesia; Reaction; Anesthesia; Adverse Effect

Summary: the research team is creating a foundational infrastructure in order to develop a precision medicine approach for geriatric patients who require surgery with anesthesia. the team plans to build the first of its kind comprehensive database of demographic and risk factor questionnaire responses, biobanked blood specimens, intraoperative electroencephalography (eeg), and inclusive cognitive testing throughout patient interaction starting at the preop appointment until a year later. this will be used to create a predictive model of periooperative neurocognitive disorders.


Eligibility criteria:
inclusion criteria: * at least 65 years old (inclusive) * non cardiac general elective surgery * general anesthesia is expected for 2+ hours exclusion criteria: * alzheimer's * dementia * parkinson's * history of neurodegenerative diseases * medication for depression (ie. benzodiazepines) * alcoholism * discretion of pi
to compare the effectiveness of suvorexant vs placebo on sleep pressure in hypertensives with insomnia

Conditions: Hypertension; Insomnia

Summary: the purpose of this study is to compare the effectiveness and safety of suvorexant versus placebo on sleep pressure and circadian rhythm in hypertensives with insomnia.

the study consists of a 4-week run-in period and a 2-week treatment period.

Eligibility criteria:
inclusion criteria: \[at interim registration\] patients who meet the following criteria are eligible for the study: 1. patients who give written consent of agreement to voluntarily participation in the clinical study 2. age 20 years or older 3. sex: male or female 4. treatment classification: outpatient 5. hypertensive patient who meet at least one of the following: * under antihypertensive medications * clinic systolic blood pressure (sbp) less than 160 mmhg 6. patients with insomnia who meet at least one of the following: * patients with any one of the following symptoms twice a week or more and at least 1 month-continuation: difficulty initiating sleep (time to sleep onset 2 hours or more longer than usual), difficulty maintaining sleep (awakening twice or more in the night), early morning awakening (awakening 2 hours or more earlier in the morning than usual), difficulty sleeping deeply (no soundly asleep feeling at the time of awakening in the morning). b. patients with interference with social or occupational function due to the above insomnia symptoms \[at official registration\] patients who meet the following criteria at the end of run-in period are eligible for the study: 1. stable unchanged antihypertensive medication for run-in period. 2. average morning home sbp more than 135 mmhg during 5 days before the end of run-in period. exclusion criteria: 1. patients with serious liver disease. 2. patients with serious respiratory disease. 3. patients with secondary hypertension 4. patients with sleep apnea syndrome 5. patients with history of narcolepsy or cataplexy 6. patients with history of organic cerebral disorders 7. patients with history of hypersensitivity to suvorexant 8. patients received cyp3a strongly-inhibitors including itraconazole, clarithromycin and ritonavir, saquinavir, nelfinavir, indinavir, telaprevir and voriconazole at the start of the run-in period 9. patients with average clinic sbp of 160 mmhg or more at the start of the run-in period 10. patients received suvorexant and other hypnotic at the start of the run-in period on a regular basis 11. patients who are breast-feeding, pregnant, possibly pregnant, or plan to become pregnant 12. patients who are considered not to be eligible for this study by their investigator or sub-investigator
microbiome, exercise tracking study: among individuals at high risk for colorectal cancer

Conditions: Colorectal Cancer

Summary: the purpose of this study has 2 aims: aim 1: to demonstrate the feasibility of recruiting and retaining adults at high risk of colorectal cancer to a physical activity intervention trial. investigators hypothesize that it will be possible to recruit and retain this patient population to a physical activity intervention trial. aim 2: to demonstrate the feasibility of collecting, processing, storing stool samples and analyzing the gut microbiome data. investigators hypothesize that all of these steps are feasible.

colorectal cancer (crc) is the second leading cause of cancer-related deaths in the u.s. and is the third most common cancer in men and women. crc risk factors include genetic predisposition, host factors and modifiable lifestyle behaviors (e.g., diet, physical activity, obesity). there are very limited data on the differences in the gut microbiota among populations at different levels of crc risk, as well as the effects of behavioral interventions to alter the gut microbiome.

Eligibility criteria:
inclusion criteria: 1. fluent in english or spanish; 2. at high risk of developing colorectal cancer; 3. no history of colorectal cancer, including germ-line heritable colorectal cancers such as familial adenomatous polyposis (fap) and hereditary nonpolyposis colorectal cancer (hnpcc); 4. no use of antibiotics in the previous 3 months; or current regular use of antibiotics 5. access to either smart phone or computer; and 6. currently physically inactive. exclusion criteria: any criterion not met under inclusion.

Keywords: gut microbiota butyrate physical activity
circulating cell-free tumor dna(ctdna) in pancreatic cancer

Conditions: Pancreatic Cancer

Summary: the aim of the study is to evaluate whether peripheral circulating cell-free tumor dna(ctdna) can help early screening of pancreatic cancer recurrence or not. and we are also planning to evaluate correlation between ctdna with clinical outcome of pancreatic cancer.

in the formation and growth of a primary tumor, cells can released into the bloodstream. there are many researches for these circulating tumor cells(ctc) and recently circulating cell-free tumor dna(ctdna) released from apoptotic or necrotic tumor cells has developed. at one report which checked ctdna level after operation of colon cancer patients, they suggested that ctdna could show recurrence of cancer several months earlier than the conventional follow up imaging. and several reports suggested that ctdna can invade host cell and change host cell biology, which can evoke cancer metastasis. so in this study, the investigator will collect ctdna of pancreatic cancer patients, benign pancreatic disease patients, and healthy population. and the investigator will evaluate whether peripheral ctdna can help early screening of cancer recurrence. and we will study about genomic signature of ctdna to evaluate relationship between ctdna and clinical outcome of cancer patients.

Eligibility criteria:
inclusion criteria: * comparative group : pancreatic cancer patients who progress endoscopic ultrasonography fine-needle aspiration (eus-fna) for pancreatic cancer diagnosis, pancreatic cancer patients who are in operable stage * control group : benign pancreas disease patients who progress eus-fna for diagnosis, healthy population exclusion criteria: * foreigners * pancreatic cancer patients who have other cancer * patients who impossible to consent to study by own

Keywords: pancreatic cancer recurrence dna
polyphenols, exercise, and metabolomics

Conditions: Exercise-induced Inflammation; Exercise-induced Oxidative Stress; Exercise-induced Immune Dysfunction

Summary: nutrasorb is a newly developed food product (see www.nutrasorb.com). this study will use the nutrasorb soy protein product that is matrixed with polyphenols from blueberries and green tea extract, and test for efficacy as a nutritional countermeasure to exercise-induced physiologic stress (i.e., immune dysfunction, inflammation, and oxidative stress) using both traditional and metabolomics-based outcome measures.


Eligibility criteria:
inclusion criteria: * male or female endurance athletes; competitive runners or cyclists * capable of exercising for 2.5 h at a high intensity in the lab * ages 18-55 * agree to train normally and stay weight stable. * agree to avoid the use of large dose vitamin/mineral supplements * agree to avoid herbs and medications that influence inflammation exclusion criteria: * regularly take supplements or medicines known to effect inflammation. * at moderate or high risk for cardiovascular disease. * younger than 18 or older than 55 years of age. * no history of competing in long distance running and cycling races.

Keywords: inflammation oxidative stress immune dysfunction metabolomics.
monitoring of bone free flaps with microdialysis

Conditions: Microsurgery; Head and Neck Reconstructive Surgery; Head and Neck Cancer; Head and/or Neck Shotgun Trauma; Bone Free Flap

Summary: microdialysis is admitted to be reliable by numerous surgeons to monitor flaps. nevertheless, a few authors reported follow up with microdialysis in bone flaps, and they all described the position of the catheter in the surrounding soft tissue muscle. this surrounding soft tissue is not always the reflect of bone vascularisation. the aim is to study the feasibility of a follow up of microanastomosed bone flaps with microdialysis. to reach this goal, investigators perform a clinical prospective research project untitled mtm project

in addition to our classical clinical monitoring, bone microanastomosed flaps for reconstructive facial surgery will be monitored with cma 70 catheter directly positioned in bone tissue. the monitoring is recorded during 5 days. glucose, lactate , pyruvate , glycerol rates will be analysed : * every hour at day 1, * every two hours at day 2, * every three hours at day 3,4 and 5. data are managed with labpilot software.

Eligibility criteria:
inclusion criteria: * head and neck reconstruction with iliac crest or fibula free flaps * informed consent obtained exclusion criteria: * reconstruction with other types of free flaps

Keywords: microdialysis bone free flap head and neck monitoring free flap reconstructive surgery
effects of bile acids and bile acid sequestrants on glp-1 secretion after roux-en-y gastric bypass

Conditions: Severe Obesity

Summary: the purpose of this study is to examine the effects of bile acid and bile acids sequestrants on glp-1 secretion, during a meal, in patients after roux-en-y gastric bypass.


Eligibility criteria:
inclusion criteria: * uncomplicated rygb performed minimum 3 months prior to the study. * fasting plasma glucose \< 7,0 mm, hba1c \< 48 mmol/mol 3 months after rygb exclusion criteria: * fasting plasma glucose \> 7,0 mm, hba1c \> 48 mmol/mol 3 months after rygb. * dysregulated thyroid diseases, use of antithyroid treatment. * late diabetic complications as retinopathy, renal insufficiency, neuropathy or previous pancreatitis. * complications to rygb. documented reactive hypoglycaemia, severe dumping (vomiting, diarrhea, severe abdominal pain after food intake). * cholecystectomy
effect of hyaluronic acid and single dose corticosteroid injection to improve wound healing in controlled diabetic patients post tooth extraction.

Conditions: Diabetes Mellitus; Wound Healing Delayed

Summary: the goal of this clinical trial is to learn if hyaluronic acid and corticosteroid improves wound healing in diabetic patients after oral extraction.

after sample size estimation via open epi of 128, randomized clinical trial was performed on the patients from oral and maxillofacial surgery department in madinah teaching hospital, faisalabad. patients were divided into three groups. group 1 was subjected as control group, group 2 was treated post extraction with 0.2 % hyaluronic acid (gengigel gingival gel 20ml, ricerfarma, milan, italy) and group 3 was treated with single dose hy-cortisone injection 250 mg (generic name: hydrocortisone sodium succinate, cirin pharmaceuticals pakistan) intramuscularly after extraction. wound healing was assessed through landry healing index. one-way anova test was applied for comparative analysis and post hoc tuckey's test was applied for pairwise comparisons between the groups

Eligibility criteria:
inclusion criteria: * • controlled diabetic patients who had random blood glucose levels of 80 to 130 mg/dl, according to world health organization. * age was defined from 25-55, irrespective of the gender. * tooth extractions in maxilla or mandible without the presence of an acute infection or compromised periodontal state. exclusion criteria: * • patients who declined to participate. * patients below the age of 25 and above the age of 55. * patients with uncontrolled diabetes mellitus (blood sugar levels high than the defined range) * patients with history of adverse effects to local anesthetics or who are currently taking corticosteroids. * patients with unmaintained oral hygiene and smoking habits. * confirmation of any chronic illness, including those with hypertension or cardiac disorders. * patients who have undergone any recent major surgical procedure.

Keywords: wound healing post extraction, single dose corticosteroid, diabetes mellitus, hyaluronic acid
investigation of the performance and safety of new 1-piece open ostomy appliances compared to standard care

Conditions: Ileostomy - Stoma

Summary: to assess the functionality and safety of the test products and also assess the products' ability to collect stool without interfering with the stoma. the degree of leakage using the product will also be measured


Eligibility criteria:
inclusion criteria: * have given written informed consent * be at least 18 years of age and have full legal capacity * be able to handle the bags themselves or with help from caregiver * have an ileostomy with a diameter between 15 and 45 mm * have had their ostomy for at least three months * currently use a 1-piece flat standard care product with open bag * negative result of a pregnancy test for women of childbearing age * custom-cut product user * be suitable for participation in the investigation exclusion criteria: * use irrigation during the study (flush the stoma with water) * currently receiving or have within the past 2 months received radio- and/or chemotherapy * currently receiving or have within the past month received local or systemic steroid treatment in the peristomal area * are pregnant or breastfeeding * participating in other interventional clinical investigations or have previously participated in this investigation * max three days wear time * suffer from peristomal skin problems that preclude participation in the investigation (assessed by the investigation nurse)
a study to examine the, safety, tolerability and pharmacokinetics co-administered baclofen and memantine in obese and lean, otherwise healthy adults

Conditions: Healthy Volunteers;; Obese, Otherwise Healthy Volunteers

Summary: the purpose of this study is to investigate the safety, tolerability and pharmacokinetics of a predefined dose range of co-administered baclofen and memantine in non-obese (part a) and obese (part b), otherwise healthy subjects.


Eligibility criteria:
inclusion criteria: 1. adult males or females aged 18 to 45 years inclusive; 2. subjects with body mass index: for part a: ≥18 kg/m² and ≤25 kg/m²; for part b: ≥33 kg/m² and ≤40 kg/m². 3. subjects with a total body weight of ≥50 kg (part a and part b); 4. subjects who are healthy as determined by the investigator based on pre study medical history, physical examination, vital signs (blood pressure, pulse rate, respiratory rate and body temperature) and 12-lead ecg at screening and each admission; 5. subjects whose clinical laboratory test results are not clinically relevant and are acceptable to the investigator at screening and each admission; 6. aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase and bilirubin ≤1.5 x upper limit of normal (uln); 7. subjects who are negative for hepatitis b surface antigen (hbsag), hepatitis c antibody and human immunodeficiency virus (hiv) i and ii tests at screening; 8. subjects who are negative for drugs of abuse and alcohol tests at screening and each admission; 9. subjects who are non-smokers or who have not smoked or used nicotine-containing products for at least 3 months prior to screening; 10. subjects with an estimated creatinine clearance ≥100 ml/minute for male subjects or ≥90 ml/minute for female subjects (cockcroft-gault method) at screening; 11. subjects who are able and willing to give written informed consent.